AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Reply to Gachabayov et al: Consensus Statement on TaTME: Other Thoughts

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1762738> since 2020-11-17T10:07:24Z

Published version:

DOI:10.1111/codi.15434

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

29 November – 2 December 2020, St.Gallen, Switzerland

European Colorectal Congress

JOIN THE VIRTUAL
EUROPEAN COLORECTAL
CONGRESS 2020

Sunday, 29 November 2020

MASTERCLASS

12.50
Introduction & course objectives
Michel Adamina, Winterthur, CH

13.00
Myths and facts about oral
antibiotics, bowel preparation,
and timing of iv antibiotics to
reduce surgical site infection
Frédéric Ris, Geneva, CH

13.40
Management of colorectal GIST –
all you should know from diagnosis
to handling recurrences
Paris Tekkis, London, UK

14.20
Handling large rectal adenoma
and malignant polyps
Roel Hompes, Amsterdam, NL

15.00
What your pathologist can do
for you: from standard margins
recommendations to molecular
pathology, liquid biopsies,
and the microbiome
Phil Quirke, Leeds, UK

15.40
Prehabilitation, patient blood
management, frailty index –
welcome addition or resource
wasting
Des Winter, Dublin, IR

16.20
Selective use of neoadjuvant
and adjuvant radiotherapy for
rectal cancer
Chris Cunningham, Oxford, UK

17.00
Do and don't in taTME surgery –
a decade of experience explained
Willem Bemelman, Amsterdam, NL

17.40
All techniques to avoid staple line
intersections in colorectal surgery
Antonino Spinelli, Milano, IT

18.20
Management of pelvic sepsis after
colorectal / coloanal anastomosis
and oncological outcomes of the
GRECCAR 5 trial
Quentin Denost, Bordeaux, FR

19.00
Best practices in colostomy
construction and repair of
parastomal hernia
Eva Angenete, Göteborg, SE

Sunday, 29 November 2020

COURSE IN PROCTOLOGY

12.50
Introduction & course objectives
Bruno Roche, Geneva, CH

13.00
Complex anorectal fistula revisited:
established wisdom and innovative
approaches
Alexander Herold, Mannheim, DE

13.30
Diagnosis and repair of childbirth
and pelvic floor trauma
Isabelle Kaelin Gambirasio
Geneva, CH

14.00
The painful bottom –
Proctalgia beyond the classical
abscess, fissures, and hemorrhoids
Bruno Roche, Geneva, CH

14.30
Sexually transmitted diseases
in proctology
Karel Skala, Geneva, CH

15.00
Anorectal trauma and foreign
bodies
Richard Cohen, London, UK

15.30
Pilonidal sinus –
strategies and outcomes
Frédéric Ris, Geneva, CH

16.00
Fecal incontinence:
investigations and conservative
treatment
Beatrice Salvioli, Milano, IT

16.30
Fecal incontinence:
neuromodulation and
interventional options
Joan Robert-Yap, Geneva, CH

17.00
The pelvic floor revealed:
transperineal / transvaginal /
transanal repairs explained
Bruno Roche, Geneva, CH

17.30
The pelvic floor revealed:
investigations and pelvic floor
therapy
Jacqueline de Jong, Bern, CH

18.00
Obstructed defecation and IBS:
investigations, differential
diagnosis, and treatment strategies
Daniel Pohl, Zurich, CH

18.30
Obstructed defecation:
surgical options
André d'Hoo, Leuven, BE

Monday, 30 November 2020

SCIENTIFIC PROGRAM

13.50
Opening and welcome
Jochen Lange, St. Gallen, CH

14.00
Is cancer an infectious disease:
role of the microbiome
Philip Quirke, Leeds, UK

14.30
Ethical considerations in crisis –
lessons from Covid-19
Omar Faiz, London, UK

15.00
Prophylactic mesh in colorectal
surgery
René H. Fortelny, Wien, AT

15.30
Lars Pahlman lecture:
Extending the limits of liver
surgery
Markus Büchler, Heidelberg, DE

16.00
Multimodal approaches to
colorectal liver metastases
Mohammed Abu Hilal, Brescia, IT

16.30
SATELLITE SYMPOSIUM Ethicon
ETHICON
Shaping the future
of surgery

17.00
Urogenital dysfunction in
patients treated for rectal cancer –
what do we know and what
can we do?
Eva Angenete, Göteborg, SE

17.30
Hemorrhoids –
new options and time-tested
solutions
Alexander Herold, Mannheim, DE

18.00
Anal pain and emergency
proctology: what every surgeon
should know & do
Richard Cohen, London, UK

18.30
All you need to know about
anorectal fistula
Bruno Roche, Genève, CH

19.00
SATELLITE SYMPOSIUM Medtronic
Medtronic
Further Together

19.45
Strategies and outcomes for
obstructive cancers of the colon
and rectum
Willem Bemelman, Amsterdam, NL

Tuesday, 1 December 2020

SCIENTIFIC PROGRAM

14.00
Lessons learned along the robotic
learning curve: a video guide for
colorectal surgeons
Jim Khan, Portsmouth, UK

14.30
EAES presidential lecture:
Strategies for lifelong learning
and implementation of new
technologies
Andrea Pietrabissa, Pavia, IT

15.00
SATELLITE SYMPOSIUM Intuitive
INTUITIVE

15.45
A journey in global surgery –
why getting out of the comfort
zone
Raffaele Rosso, Lugano, CH

16.15
Enhanced recovery pathways
reloaded – a practical guide to
success
Roberto Persiani, Roma, IT

16.45
Cancer at the extremes of age:
are there any differences in
handling youngsters and seniors
Des Winter, Dublin, IE

17.15
SATELLITE SYMPOSIUM BBraun
B BRAUN
SHARING EXPERTISE

TOUCHSTONE
Leading through Innovation

18.00
Management pearls for early
rectal cancer
Roel Hompes, Amsterdam, NL

18.30
Ventral rectopexy:
indications, tricks of the trade,
and long-term results
Chris Cunningham, Oxford, UK

19.00
Total neoadjuvant therapy
for colon and rectum cancers
Ronan O'Connell, Dublin, IE

Wednesday, 2 December 2020

SCIENTIFIC PROGRAM

14.00
Randomized trial evaluating
chemo-therapy followed by
pelvic reirradiation vs chemo-
therapy alone as preoperative
treatment for locally recurrent
rectal cancer (GRECCAR 15)
Quentin Denost, Bordeaux, FR

14.30
Timeline of surgery following
neoadjuvant radiotherapy –
balancing morbidity and efficacy
Torbjörn Holm, Stockholm, SE

15.00
Place and outcome of total
colectomy in the surgical
armamentarium
Neil Mortensen, Oxford, UK

15.30
Kono S anastomosis and
over the valve stricturoplasties:
hope for better outcomes
André d'Hoo, Leuven, BE

16.00
New drugs, old fears:
state of the art management
of IBD patients
Gerhard Rogler, Zurich, CH

16.30
Do resection of the mesentery
in Crohn's & appendectomy
in ulcerative colitis alter the
course of disease
Christianne Buskens, Amsterdam, NL

17.00
SATELLITE SYMPOSIUM Takeda
Takeda

17.45
The septic abdomen:
getting out of misery and
closing the case
Marja Boermeester, Amsterdam, NL

18.15
Management strategies
for patients with advanced
colorectal cancers
Paris Tekkis, London, UK

18.45
Anastomotic leak in colorectal
surgery: insights, perspectives,
and practical strategies
Antonino Spinelli, Milano, IT

19.15
Closing words
Michel Adamina, Winterthur, CH

Information & Registration

www.colorectalsurgery.eu

The publication of this advertisement does not constitute endorsement by the society, publisher, or Editors, and is unrelated to the content that follows

Article type : Correspondence

Reply to Gachabayov et al: Consensus Statement on TaTME: Other Thoughts

On behalf of the TaTME Guidance group representing the ESCP (European Society of Coloproctology), in collaboration with ASCRS (American Society of Colon and Rectum Surgeons), ACPGBI (Association of Coloproctology of Great Britain and Ireland), ECCO (European Crohn's and Colitis Organisation), EAES (European Association of Endoscopic Surgeons), ESSO (European Society of Surgical Oncology), CSCRS (Canadian Society of Colorectal Surgery), CNSCRS (Chinese Society of Colorectal Surgery), CSLES (Chinese Society of Laparo-Endoscopic Surgery), CSSANZ (Colorectal Surgical Society of Australia and New Zealand), JSES (Japanese Society of Endoscopic Surgery), SACP (Argentinian Society of Coloproctology), SAGES (Society of American Gastrointestinal and Endoscopic Surgeons), SBCP (Brazilian Society of Coloproctology) and the Swiss-MIS (Swiss association for Minimally Invasive Surgery)

Participants (in alphabetical order by surname):

Michel Adamina, Felix Aigner, Sergio Araujo, Alberto Arezzo, Shady Ashamalla, Teresa deBecheAdams, Stephen Bell, Willem Bemelman, Carl Brown, Walter Brunner, Nicolas Buchs, Antonio Caycedo, Sami Chadi, Park Sung Chan, David Clark, Quentin Denost, André D'Hoore, Nicola Fearnhead, Nader Francis, Eelco de Graaf, Suguru Hasegawa, Julian Hayes, Alexander Heriot, Roel Hompes, Bert Houben, Masaaki Ito, Mark Katory, Jos Kleijnen, Werner Kneist, Joep Knol, Tsuyoshi Konishi, John Marks, Beatriz Martin-Perez, Justin Maykel, Elisabeth McLemore, Danilo Miskovic, Isacco Montroni Gabriela Möslin, Jae Hwan Oh, Rodrigo Oliva Perez, Marta Penna, Frederic Ris, Gustavo Rossi, Eric Rullier, Gerald Seitingner, Antonino Spinelli, Andrew Stevenson, Patricia Sylla, Ichiro Takemasa, Pieter Tanis, Jared Torkington, Jurriaan Tuynman, Elena Vikis, Janindra Warusavitarne, Mark Whiteford, Hongwei Yao, Seong Hyeon Yun, Zhongtao Zhang, Minhua Zheng

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/CODI.15434](#)

This article is protected by copyright. All rights reserved

Correspondence:

Roel Hompes, MD, PhD

Department of Surgery, Amsterdam University Medical Centres - location AMC

University of Amsterdam

Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Email: r.hompes@amc.uva.nl

Tel: +31 20 – 5662660

Dear Editor,

We thank Gachabayov *et al* for their thoughts and appreciation of our recently published International Expert Consensus Guidance on TaTME [1], and the opportunity to clarify any misunderstandings regarding its purpose and methodology. Firstly, the panellists consisted of 56 internationally known and respected surgeons, experienced in managing rectal cancer not only by TaTME but also by the abdominal approaches. They have performed over 50 TaTME cases each, taught on cadaveric courses, and published literature on the technique. They were also identified and recommended by their national colorectal surgical societies. Given that the aim of the consensus was to formulate guidance specifically on the safe implementation and application of TaTME, rather than the management of rectal cancer as a whole, it is very reasonable for the panel to be composed of practicing surgeons experienced in TaTME. The number of panellists allowed us to bring together the worldwide experience of the technique, with representatives from each of the 14 international societies who also recognised and endorsed the importance of this project. Five rounds of Delphi were required to reach agreement on the statements over three years, suggesting that conformity bias was unlikely as each surgeon clearly expressed their opinion leading to many hours of discussion. The authors quote that 16% of the panellists have a conflict of interest. As stated on the consensus article and on the contrary to another misleading consideration, none of the participants have any direct conflict of interest with regards to the paper. To be open and transparent however we listed commitments with industry by individual

participants. It is not unusual, and in the current era of advancing technical innovation, for specialist senior surgeons to consult and provide direction for these companies.

Secondly, the methodology used consisted of an adapted Delphi method and focus group discussion approach, guided by an expert in guidelines methodology. Consensus was considered achieved when agreement level of >80% was reached. The authors reference a perspective on the Delphi process by Waggoner et al [2] in which the opinion of the three authors was to only include a panel size of 6 – 11 members, based on a few studies and “the lack of current research” [2]. This is in contrast to an extensive set of experiments conducted at the RAND corporation which clearly showed a positive correlation between increasing number of participants with accuracy and reliability of the responses [3]. The size of the panel in most Delphi studies is incredibly variable [2], and often reflects the research question and underlying purpose of conducting the Delphi process which may well lead to varying numbers of participants.

The guidance group acknowledged that at the present time there is no level 1 evidence on TaTME. However, published evidence is accumulating rapidly and, hence we proposed the new concept of “dynamic guidance”, whereby the guidance could be updated as more evidence becomes available. Randomised controlled trials such as COLOR III [4] and ETAP-GRECCAR11 [5] have started patient recruitment but results will not be available for some time. Given the dynamic character of the statements, we also strongly advocated all societies to publish these guidance statements online for review and critical appraisal of their respective membership. Peer review by the wider colorectal community will allow further adaptation and improvement of the current statements.

We agree that “Clinical expertise in the era of evidence-based medicine and patient choice should be integrated with evidence, patients’ preferences, and clinical circumstances” [6].

However, in the context of surgical innovation this is not so straight forward as a technique (and the surgeon’s skill in performing it) may still be evolving and its true benefits and risks not fully known yet.

TaTME is currently in the early part of the assessment phase of the IDEAL framework for surgical innovation [7]. Despite following the IDEAL recommendations and steps closely, especially during the early development of the technique [8], the explorative phase saw a huge surge in TaTME adoption worldwide. This was largely unregulated and unstructured with variable access

to adequate training and provision of experienced proctors. Unsurprisingly, problems soon arose with concerns regarding urethral injuries [8], CO2 embolus [10] and more recently local recurrence [11,12]. It is exactly during these times of widespread discussion and concern about a technique that a consensus is needed. Although the panellists in this consensus may be viewed as being “in favour of TaTME” simply because they perform the technique, the guidance produced actually calls for caution and sets more preconditions and direction for surgeons considering adopting TaTME. By having personally faced the challenges that TaTME can bring, the panellists acknowledge that certain standards and pre-requisites are necessary in order to safely implement the technique. Pre-requisites, such as a minimum annual volume of TME cases, obtaining appropriate training and acquiring advanced surgical skills, are not achievable in every colorectal unit; thus limiting the adoption of TaTME. Furthermore, by setting these standards through the consensus process, self-licensing is more likely to be prevented.

Finally, we feel that the statement “the concept of expert centers is outdated” is incorrect. Expert centres for novel and challenging techniques are vitally important for their safe introduction. Parallels have already been seen with minimally invasive oesophagectomy [13] and endovascular aortic aneurysm repair [14]. The definition of ‘expert centre’ in our consensus contained three components: 1) Centre specifications; 2) Surgeon expertise; 3) Centre performance/outcomes. The latter two categories actually achieved agreement levels of 97.9% and 91.7%, respectively. Only ‘centre specifications’ obtained 62.5% agreement despite lengthy discussions and a further Delphi round. The discussion points regarding this component highlighted the diversity in surgical practice and resource availability around the globe. However, the panellists agreed that complex high-risk cases should not be performed in low volume units sporadically by inexperienced surgeons. Regular exercise of an activity or skill is the way to become proficient in it, hence the importance of securing a high case volume in a well-resourced department.

In conclusion, TaTME captured the colorectal community’s attention, due to perceived advantages, and enthusiasm has led to widespread uncontrolled adoption. This occurred despite the lack of high-level evidence of its equivalence to conventional TME approaches. The International Expert Consensus Guidance aims to promote a more cautious and considered roadmap for the introduction of this new technique into clinical practice. With strong

collaboration, sharing of experiences, high-quality research and regular review of available evidence, surgical innovation can continue to evolve and allow us to provide better patient care.

References

1. TaTME Guidance Group representing the ESCP (European Society of Coloproctology), in collaboration with the ASCRS (American Society of Colon and Rectal Surgeons), ACPGBI (Association of Coloproctology of Great Britain and Ireland), ECCO (European Crohn's and Colitis Organisation), EAES (European Association of Endoscopic Surgeons), ESSO (European Society of Surgical Oncology), CSCRS (Canadian Society of Colorectal Surgery), CNSCRS (Chinese Society of Colorectal Surgery), CSLES (Chinese Society of Laparo-Endoscopic Surgery), CSSANZ (Colorectal Surgical Society of Australia and New Zealand), JSES (Japanese Society of Endoscopic Surgery), SACP (Argentinian Society of Coloproctology), SAGES (Society of American Gastrointestinal and Endoscopic Surgeons), SBCP (Brazilian Society of Coloproctology), Swiss-MIS (Swiss Association for Minimally Invasive Surgery). International expert consensus guidance on indications, implementation and quality measures for transanal total mesorectal excision. *Colorectal Dis.* 2020;22(7):749-755.
2. Waggoner J, Carline JD, Durning SJ. Is There a Consensus on Consensus Methodology? Descriptions and Recommendations for Future Consensus Research. *Acad Med.* 2016;91(5):663-8.
3. Dalkey NC. The Delphi method: an experimental study of group opinion, the RAND corporation. RM-5888-PR, 1969.
4. Deijen CL, Velthuis S, Tsai A, et al. COLOR III: A Multicentre Randomised Clinical Trial Comparing Transanal TME Versus Laparoscopic TME for Mid and Low Rectal Cancer. *Surg Endosc* 2016;30(8):3210-3215.

- Accepted Article
5. Lelong B, de Chaisemartin C, Meillat H, et al.; French Research Group of Rectal Cancer Surgery (GRECCAR). A Multicentre Randomised Controlled Trial to Evaluate the Efficacy, Morbidity and Functional Outcome of Endoscopic Transanal Proctectomy Versus Laparoscopic Proctectomy for Low-Lying Rectal Cancer (ETAP-GRECCAR 11 TRIAL): Rationale and Design. *BMC Cancer*. 2017;11;17(1):253.
 6. Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice. *Vox Sang*. 2002;83 Suppl 1:383-6.
 7. McCulloch P, Altman DG, Campbell WB et al. Balliol Collaboration. No surgical innovation without evaluation: the IDEAL recommendations. *Lancet* 2009;374:1105–1112.
 8. Roodbeen SX, lo Conte A, Hirst A, et al. Evolution of transanal total mesorectal excision according to the IDEAL framework. *BMJ Surg Interv Health Technologies* 2019;1:e000004. doi:10.1136/bmjst-2019-000004
 9. Sylla P, Knol JJ, D'Andrea AP, Perez RO, Atallah SB, Penna M, Hompes R, Wolthuis A, Rouanet P, Fingerhut A; International taTME Urethral Injury Collaborative. Urethral injury and other urological injuries during transanal total mesorectal excision: An International Collaborative Study. *Ann Surg*. 2019 Sep 17. doi: 10.1097/SLA.0000000000003597. Online ahead of print.
 10. Dickson EA, Penna M, Cunningham C, et al. On behalf of the International TaTME registry collaborative. Carbon Dioxide Embolism Associated with Total Mesorectal Excision Surgery: A Report from the International Registries. *Dis Colon Rectum* 2019; 62(7):794-801.
 11. Wasmuth HH, Faerden AE, Myklebust TA, et al., Norwegian TaTME Collaborative Group, on behalf of the Norwegian Colorectal Cancer Group. Transanal Total Mesorectal Excision for Rectal Cancer Has Been Suspended in Norway. *Br J Surg* 2020; 107(1):121-130.
 12. van Oostendorp SE, Belgers HJ, Bootsma BT, et al. Locoregional recurrences after transanal total mesorectal excision of rectal cancer during implementation. *Br J Surg* 2020 Apr 4;107(9):1211-1220
 13. Markar SR, Ni M, Gisbertz SS, van der Werf L, Straatman J, van der Peet D, Cuesta MA, Hanna GB, van Berge Henegouwen MI; Dutch Upper GI Cancer Audit and TIME Study Group. Implementation of Minimally Invasive Esophagectomy From a Randomized

Controlled Trial Setting to National Practice. J Clin Oncol. 2020 Jul 1;38(19):2130-2139.

doi: 10.1200/JCO.19.02483. Epub 2020 May 18. PMID: 32421440.

14. Karthikesalingam A, Holt PJ, Vidal-Diez A, Bahia SS, Patterson BO, Hinchliffe RJ, Thompson MM. The impact of endovascular aneurysm repair on mortality for elective abdominal aortic aneurysm repair in England and the United States. J Vasc Surg. 2016 Aug;64(2):321-327.e2. doi: 10.1016/j.jvs.2016.01.057. Epub 2016 Apr 1.